Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New muscle scanner could help seniors stay independent longer

NCT ID NCT06963359

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new technology (HD-sEMG) that monitors muscle signals to better diagnose sarcopenia—a condition where older adults lose muscle mass and strength. Researchers will enroll 846 people aged 75 and older who are hospitalized and at risk for sarcopenia. The goal is to see if this technology can accurately identify those with the condition, helping doctors intervene earlier to prevent falls and loss of independence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 846 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

75 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 75 years and over * Score ≥4 on the SARC-F screening questionnaire * Enrolled in a social security plan (no AME) * Informed and consenting patient Exclusion Criteria: * BMI ≥30 kg/m2 * Severe psychiatric pathology or severe cognitive disorders that do not allow the performance of examinations * Patients who are dependent for all acts of daily life * Patients with a very short life expectancy \<3months * Pace maker * Recent fracture or trauma of the preventing dynamic measurement of HD-sEMG recording * Bilateral hip prosthesis * Skin problem that may interfere with the recording of surface EMG activity * Skin allergies to plasters * Allergies to electrode materials (acrylate) * Patient under legal protection * Patient on state medical aid (AME : Aide Médicale d'Etat)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Bichat, APHP

    RECRUITING

    Paris, 75018, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Corentin Celton, APHP

    RECRUITING

    Issy-les-Moulineaux, 92130, France

  • Hôpital Corentin Celton, APHP

    RECRUITING

    Issy-les-Moulineaux, 92130, France

  • Hôpital Rothschild, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Rothschild, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Saint-Antoine, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Tenon, APHP

    RECRUITING

    Paris, 75020, France

  • Unité d'Explorations fonctionnelles du sujet âgé - Hôpital Charles Foix

    NOT_YET_RECRUITING

    Ivry-sur-Seine, 94205, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.